{"filing":{"accession_number":"0001651308-26-000025","cik":"0001651308","ticker":"BEIGF","company_name":"BeOne Medicines Ltd.","form":"8-K","filing_date":"2026-08-26","report_date":"2026-08-26","primary_document":"bgne-20260826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000025/bgne-20260826.htm"},"events":[{"id":29597,"run_id":27110,"accession_number":"0001651308-26-000025","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"BeOne Medicines filed its 2026 Interim Report for the six months ended June 30, 2026 with the Shanghai Stock Exchange on August 26, 2026, and disclosed supplemental financial information including R\u0026D expenses by product pipeline and reconciliation of key accounting differences between PRC GAAP and U.S. GAAP. While the primary report is filed in China, the 8-K Item 2.02 disclosure and Exhibit 99.1 furnish interim financial results and material accounting policy differences to U.S. investors, consistent with earnings_release classification for interim period financial disclosures.","company_name":"BeOne Medicines Ltd.","ticker":"BEIGF","filing_date":"2026-08-26","form":"8-K","submitted_at":null,"items":[{"id":31928,"accession_number":"0001651308-26-000025","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BeOne Medicines filed its 2026 Interim Report for the six months ended June 30, 2026 with the Shanghai Stock Exchange on August 26, 2026, and disclosed supplemental financial information including R\u0026D expenses by product pipeline and reconciliation of key accounting differences between PRC GAAP and U.S. GAAP. While the primary report is filed in China, the 8-K Item 2.02 disclosure and Exhibit 99.1 furnish interim financial results and material accounting policy differences to U.S. investors, consistent with earnings_release classification for interim period financial disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:15:47.761485+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31928,"accession_number":"0001651308-26-000025","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BeOne Medicines filed its 2026 Interim Report for the six months ended June 30, 2026 with the Shanghai Stock Exchange on August 26, 2026, and disclosed supplemental financial information including R\u0026D expenses by product pipeline and reconciliation of key accounting differences between PRC GAAP and U.S. GAAP. While the primary report is filed in China, the 8-K Item 2.02 disclosure and Exhibit 99.1 furnish interim financial results and material accounting policy differences to U.S. investors, consistent with earnings_release classification for interim period financial disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:15:47.761485+00:00","company_name":"BeOne Medicines Ltd.","ticker":"BEIGF","filing_date":"2026-08-26"}]}